IBIS-II试验中早期参与者报告的症状可预测阿那曲唑依从性
基于IBIS-II预防和DCIS试验,评估阿那曲唑依从性及其与早期症状的关联。预防试验中3864名绝经后女性随机接受安慰剂或阿那曲唑,DCIS试验中2980名绝经后女性随机接受他莫昔芬或阿那曲唑。两个试验依从率均超过三分之二,治疗组间无差异,特定症状对依从性有轻微但显著影响,且随严重程度增加而增强。
要点
- 预防试验依从率65.8%,阿那曲唑与安慰剂无差异(HR=0.97,P=0.6)。
- DCIS试验依从率66.7%,阿那曲唑与他莫昔芬无差异(HR=1.06,P=0.4)。
- 多数症状轻中度,依从性随症状严重程度增加而下降, dropout最高在治疗前1.5年。
核心结论
- IBIS-II预防和DCIS试验中超过三分之二女性对治疗依从,治疗组间无差异。
- 预防试验中特定症状对依从性有轻微但显著影响,且随严重程度增加而增强。
研究设计与样本
- 预防试验随机3864名绝经后女性接受安慰剂或阿那曲唑。
- DCIS试验随机2980名绝经后女性接受他莫昔芬或阿那曲唑。
- 依从性用Kaplan-Meier法计算,所有P值为双侧。
主要发现
- 预防试验依从率65.8%:阿那曲唑65.7% vs 安慰剂65.9%,HR=0.97(0.87-1.09),P=0.6。
- DCIS试验依从率66.7%:阿那曲唑67.5% vs 他莫昔芬65.8%,HR=1.06(0.94-1.20),P=0.4。
- 预防试验中,安慰剂组报告关节痛者依从性更低(P=0.02),阿那曲唑组报告妇科症状者依从性更低(P=0.003)。
- DCIS试验中,阿那曲唑组潮热与更高依从性相关(P=0.02)。
- 两个试验中多数症状为轻度或中度,多数症状依从性随严重程度增加而下降, dropout最高在治疗前1.5年。
临床怎么用
- 促进依从性的策略应针对预防治疗的第一年。
- 关注早期症状尤其是关节痛、妇科症状和潮热,以识别依从性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anastrozole reduces breast cancer risk in women at high risk, but implementing preventive therapy in clinical practice is difficult. Here, we evaluate adherence to anastrozole in the International Breast Cancer Intervention Study (IBIS)-II prevention and ductal carcinoma in situ (DCIS) trials, and its association with early symptoms. PATIENTS AND METHODS: In the prevention trial, 3864 postmenopausal women were randomized to placebo versus anastrozole. A total of 2980 postmenopausal women with DCIS were randomized to tamoxifen versus anastrozole. Adherence to trial medication was calculated using the Kaplan-Meier method and all P-values were two-sided. RESULTS: In the prevention trial, adherence was 65.8% [anastrozole (65.7%) versus placebo (65.9%); HR = 0.97 (0.87-1.09), P = 0.6]. Adherence was lower for those reporting arthralgia in the placebo group (P = 0.02) or gynecological symptoms in the anastrozole group (P = 0.003), compared with those not reporting these symptoms at 6 months. In the DCIS study, adherence was 66.7% [anastrozole (67.5%) versus tamoxifen (65.8%); HR = 1.06 (0.94-1.20), P = 0.4]. Hot flashes were associated with greater adherence in the anastrozole arm (P = 0.02). In both studies, symptoms were mostly mild or moderately severe, and adherence decreased with increasing severity for most symptoms. Drop-outs were highest in the first 1.5 years of therapy in both trials. CONCLUSIONS: In the IBIS-II prevention and DCIS trials, over two-thirds of women were adherent to therapy, with no differences by treatment groups. Participants who reported specific symptoms in the IBIS-II prevention trial had a small but significant effect on adherence, which strengthened as severity increased. Strategies to promote adherence should target the first year of preventive therapy.
引用
- Sestak I, Smith SG, Howell A, et al. Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. Ann Oncol. 2018. PMID: 29126161. doi:10.1093/annonc/mdx713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。